HK134494A - Substituted release azelastine containing medicaments - Google Patents

Substituted release azelastine containing medicaments

Info

Publication number
HK134494A
HK134494A HK134494A HK134494A HK134494A HK 134494 A HK134494 A HK 134494A HK 134494 A HK134494 A HK 134494A HK 134494 A HK134494 A HK 134494A HK 134494 A HK134494 A HK 134494A
Authority
HK
Hong Kong
Prior art keywords
azelastine
release
containing medicaments
substituted
substituted release
Prior art date
Application number
HK134494A
Other languages
English (en)
Inventor
Helmut Dr Hettche
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of HK134494A publication Critical patent/HK134494A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Switches With Compound Operations (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Rotary Pumps (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK134494A 1988-04-20 1994-12-01 Substituted release azelastine containing medicaments HK134494A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3813244 1988-04-20

Publications (1)

Publication Number Publication Date
HK134494A true HK134494A (en) 1994-12-09

Family

ID=6352451

Family Applications (1)

Application Number Title Priority Date Filing Date
HK134494A HK134494A (en) 1988-04-20 1994-12-01 Substituted release azelastine containing medicaments

Country Status (15)

Country Link
EP (1) EP0338444B1 (fr)
JP (1) JP2950845B2 (fr)
AT (1) ATE97572T1 (fr)
AU (1) AU3318389A (fr)
CA (1) CA1325976C (fr)
DE (1) DE58906232D1 (fr)
DK (1) DK172235B1 (fr)
ES (1) ES2060685T3 (fr)
FI (1) FI891865A (fr)
HK (1) HK134494A (fr)
HU (1) HU202403B (fr)
IE (1) IE62778B1 (fr)
MC (1) MC2025A1 (fr)
PT (1) PT90308B (fr)
ZA (1) ZA892877B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
DE4207234A1 (de) * 1992-03-07 1993-09-09 Asta Medica Ag Neue aminocarbonsaeure-derivate mit antiallergischer/antiasthmatischer wirkung und verfahren zu deren herstellung
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
JP4138910B2 (ja) 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
CA2348871C (fr) 1998-11-02 2009-04-14 John G. Devane Composition a liberation modifiee multiparticulaire
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
HU230686B1 (en) 2000-10-30 2017-08-28 Euro Celtique Sa Controlled release hydrocodone compositions
EP1396263A1 (fr) * 2002-08-09 2004-03-10 Warner-Lambert Company Compositions d'enrobage pour tablettes et caplets
US20070218139A1 (en) * 2002-12-20 2007-09-20 Smith Thomas J High Pressure Compaction For Pharmaceutical Formulations
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US9987233B2 (en) 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
TR201808237T4 (tr) 2015-10-27 2018-07-23 Eupraxia Pharmaceuticals Inc Lokal anestetiklerin sürekli salım formülasyonları.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174464B1 (fr) * 1984-09-14 1990-01-03 ASTA Pharma AG Benzyl-phtalazinones substitués

Also Published As

Publication number Publication date
JP2950845B2 (ja) 1999-09-20
DE58906232D1 (de) 1994-01-05
IE62778B1 (en) 1995-02-22
JPH01311024A (ja) 1989-12-15
HU202403B (en) 1991-03-28
CA1325976C (fr) 1994-01-11
IE891263L (en) 1989-10-20
PT90308A (pt) 1989-11-10
EP0338444A1 (fr) 1989-10-25
FI891865A (fi) 1989-10-21
HUT49808A (en) 1989-11-28
DK189189A (da) 1989-10-21
MC2025A1 (fr) 1990-04-25
AU3318389A (en) 1989-10-26
DK172235B1 (da) 1998-02-02
PT90308B (pt) 1994-10-31
ES2060685T3 (es) 1994-12-01
FI891865A0 (fi) 1989-04-19
EP0338444B1 (fr) 1993-11-24
ZA892877B (en) 1989-12-27
DK189189D0 (da) 1989-04-19
ATE97572T1 (de) 1993-12-15

Similar Documents

Publication Publication Date Title
IL95691A0 (en) Thienylcarboxylates of amino alcohols,their preparation and pharmaceutical compositions containing them
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
GR3007202T3 (fr)
HK134494A (en) Substituted release azelastine containing medicaments
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
GR1003711B (el) Μεθοδος δια την παρασκευη φαρμακευτικων συνθεσεων δια συστηματικην διαδερμικην χορηγησιν.
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
NZ218028A (en) Benzimidazole derivatives and pharmaceutical compositions
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
GB8623557D0 (en) Therapeutic agents
PT86186A (en) Process for the preparation of benzimidazol derivatives and of pharmaceutical compositions containing the same
GR3006091T3 (fr)
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
DE3474774D1 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
GB2021409A (en) Pharmaceutical composition
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
HUT50787A (en) Process for producing pharmaceutical compositions comprising 4-aryl-4-piperidine-, pyrrolidine- or hexahydroazepincarbinol derivatives or heterocyclic analogs thereof as active ingredient and process for producing the new compounds
HU9700842D0 (en) Pharmaceutical compositions based on stabilized lipophyl matrix giving controlled release for the active components
EP0380989A3 (en) Plaster for transdermal administration
EP0351876A3 (fr) Composition pour augmenter l'effet de vaccination
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
AU1621888A (en) Pharmaceutical compositions for the treatment of cerebral psycho-organic syndromes
GR3031360T3 (en) Composition based on ibuprofen, for oral usage
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080414